论文部分内容阅读
目的探讨雷替曲塞单药三线化疗在晚期结直肠癌治疗中的疗效及安全性。方法选择2014年4月~2015年3月在我院收治的单药使用雷替曲塞的40例晚期结直肠患者，采用雷替曲塞单药3mg/m2，第1d，每21d为1个周期，2周期后行胸腹部CT评价疗效，并评价不良反应，评价疾病疗效直至出现疾病进展。结果40列患者中CR 0例(0%)，PR 2例(5%)，SD 22例(55%),PD 16例(40%)，总有效率(CR+PR)为5%。PFS为3.25个月。结论主要不良反应为骨髓抑制、恶性呕吐、转氨酶升高，无治疗相关性死亡患者，也无因毒性反应而推迟，反应轻微，可耐受。“,”Objective To study the clinical outcome and safety of raltitrexed single in third-line chemotherapy of advanced colorectal cancer. Method s 40 patients with advanced colorectal cancer who were administered with raltitrexed in third-line therapy between Apirl 2014 and March 2015 in our hospital were enrolled. The curative effects in each patient were evaluated every 2 cycles until the disease progression. Results There were 2 patients(5%) with PR, 22 patients (55%) with SD, and 16 patients (40%) with PD, no CR case. Median progression-free survival was 3.25 months.The main side effectswere myelosuppression, malignant vomiting,transaminase elevation, no treatment-related death in patients, and no toxicitywas postponedbecause of chemotherapy. Conclusion The raltitrexed-based treatment as the third-line therapy for advanced colorectal cancer is feasible with high clinical benefit rate and minor toxicities.